GENEVIE KNEIR: Open Payments
NPI 1760922017 · SANTA ROSA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$443 in 21 payments from 8 companies in 2025. Trend: 2023 $592 · 2024 $396 · 2025 $443
Food & beverage: $443
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $233 |
| ABBVIE INC. | 2 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $47 |
| E.R. Squibb & Sons, L.L.C. | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Neurocrine BioSciences, Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: REXULTI, VRAYLAR, CAPLYTA, ABILIFY MAINTENA, COBENFY, UZEDY, INGREZZA, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
